|
|
|
| Expression and clinical significance of miR-29 and PARK2 in serum of patients with Parkinson’s disease |
| SHI Jian YUAN Xiaoqin LUO Qian ZHANG Yun |
| Department of Neurology, Mianyang Hospital Affiliated to School of Medicine of University of Electronic Science and Technology of China Mianyang Central Hospital, Sichuan Province, Mianyang 621000, China |
|
|
|
Abstract Objective To explore the expression and clinical significance of micro RNA-29 (miR-29) and human Parkinson’s disease protein 2 (PARK2) in the serum of patients with Parkinson’s disease (PD). Methods A total of 85 patients with primary PD admitted to Mianyang Central Hospital, Sichuan Province from March 2014 to May 2020 were selected as the PD group, and 90 cases underwent healthy during physical examination in this hospital were selected as the control group. The expression level of serum miR-29 and PARK2 were detected; the diagnostic value of serum miR-29 and PARK2 expression levels for PD was evaluated by using area under curve (AUC) of receiver operating characteristic; logistic regression analysis was used to analyze the influencing factors. Results There were no significant differences in gender, age, BMI, and the proportion of hypertension between the two groups (P ＞ 0.05). The level of serum miR-29 in PD group was higher than that in control group, and the level of PARK2 in PD group was lower than that in control group (P ＜ 0.05). The high expression of miR-29 and low expression of PARK2 in serum were independent risk factors for PD (OR ＞ 1, P ＜ 0.05). ROC results showed that the AUC of combined detection of PD was higher than that of miR-29 and PARK2 alone (Z = 8.317, P ＜ 0.001; Z = 6.124, P ＜ 0.001). Conclusion The expression level of miR-29 in the serum of PD patients is increased, and the expression level of PARK2 in the serum of PD patients is decreased, both of which can be used as potential biological indicators for the early diagnosis of PD.
|
|
|
|
|
|
[1] Chang D，Nalls MA，Hallgrímsdóttir IB，et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci [J]. Nat Genet，2017，49（10）：1511-1516.
[2] 宋亚南，郁金泰，谭兰.帕金森病的危险因素及其预防[J].中华行为医学与脑科学杂志，2019，28（2）：188-192.
[3] Hayes MT. Parkinson’s Disease and Parkinsonism [J]. Am J Med，2019，132（7）：802-807.
[4] 李瑛，贾秀琴，梁佩鹏，等.帕金森病轻度认知功能障碍纹状体体积的异常改变[J].医学影像学杂志，2019，29（1）：1-6.
[5] 桂小红，王黎萍，吴承龙.早期与中晚期帕金森病非运动症状的比较以及对生活质量的影响[J].临床神经病学杂志，2019，32（1）：13-16.
[6] Bai X，Tang Y，Yu M，et al. Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease [J]. Sci Rep，2017，7（1）：1-7.
[7] 曹坤，孙良权，张业伟，等.过表达miR-29b可抑制胆管癌细胞的增殖和诱导细胞凋亡[J].南方医科大学学报，2018，38（10）：1234-1238.
[8] Ma R，Wang M，Gao S，et al. miR-29a Promotes the Neurite Outgrowth of Rat Neural Stem Cells by Targeting Extracellular Matrix to Repair Brain Injury [J]. Stem Cells Dev，2020，29（9）：599-614.
[9] Jahangard Y，Monfared H，Moradi A，et al. Therapeutic Effects of Transplanted Exosomes Containing miR-29b to a Rat Model of Alzheimer’s Disease [J]. Front Neurosci，2020，14（1）：564-569.
[10] Cognata VL，Maugeri G，D’Amico AG，et al. Differential expression of PARK2 splice isoforms in an in vitro model of dopaminergic-like neurons exposed to toxic insults mimicking Parkinson’s disease [J]. J Cell Biochem，2018，119（1）：1062-1073.
[11] 李欣，钟燕敏，王晨静.Parkin蛋白及其底物与帕金森病的研究进展[J].神经解剖学杂志，2021，37（3）：352-356.
[12] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会.中国帕金森病的诊断标准（2016版）[J].中华神经科杂志，2016，49（4）：268-271.
[13] Jiang P，Dickson DW. Parkinson’s disease：experimental models and reality [J]. Acta Neuropathol，2018，135（1）：13-32.
[14] 张天清，李小刚.帕金森病与肠道菌群的研究进展[J].中华老年心脑血管病杂志，2019，21（4）：113-115.
[15] Balestrino R，Schapira AHV. Parkinson disease [J]. Eur J Neurol，2020，27（1）：27-42.
[16] 何月月，刘思雨，黄秀美，等.帕金森病患者病耻感的研究现状[J].医学与哲学，2018，39（24）：53-56.
[17] 韩聪，姜月华，李伟.miRNA-29在高血压肾损害中的研究进展[J].中华高血压杂志，2019，27（7）：624-629.
[18] Monaghan MG，Holeiter M，Brauchle E，et al. Exogenous miR-29B Delivery Through a Hyaluronan-Based Injectable System Yields Functional Maintenance of the Infarcted Myocardium [J]. Tissue Eng Part A，2018，24（1/2）：57-67.
[19] 何丽亚，吴政治，王平，等.miR-29b在2型糖尿病和前期糖尿病患者血清中的表达及临床意义[J].安徽医药，2018，22（7）：1331-1334.
[20] Rong W，Yang L，Li CY，et al. MiR-29 inhibits neuronal apoptosis in rats with cerebral infarction through regulating Akt signaling pathway [J]. Eur Rev Med Pharmacol Sci，2020，24（2）：843-850.
[21] 刘辰庚，郝婷，杨婷婷，等.血浆外泌体microRNA-29c在阿尔茨海默病早期诊断价值的初步研究[J].中国实验诊断学，2018，22（5）：761-764.
[22] 韩凯.血清miR-103a、miR-30b、miR-29a相对表达量对帕金森病的诊断效能[J].山东医药，2017，57（11）：72-74.
[23] 谢非，郑晓省，岑志栋，等.PARK7基因突变所致早发性帕金森病遗传学分析[J].中华医学遗传学杂志，2019， 36（10）：957-960.
[24] Mizuno Y. More than 20 years of the discovery of Park2 [J]. Neurosci Res，2020，159（1）：3-8.
[25] 陈美红，岑志栋，陈悠，等.一个PARK2基因复合杂合突变导致的帕金森病家系的遗传学研究[J].中华医学遗传学杂志，2018，35（6）：815-818.
[26] 肖丹丹，常文光，法鸿鸽，等.Parkin介导的线粒体自噬：调控心血管疾病的新机制[J].心血管病学进展，2019， 40（1）：137-141. |
|
|
|
